This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Linda Pullan
Founder at Pullan Consulting


Linda Pullan is the founder of Pullan Consulting, which helps in all aspects of business development for fund raising and partnering, including outreach, evaluation, valuation, negotiation and strategy.  Linda and her team have an extensive deal sheet with more than 100 deals from company acquisitions to Phase III to preclinical candidates to technologies, with deals and clients in the US, Europe, and Asia.  

After a Ph.D. in Biochemistry, Linda has over 30 years of industry experience, starting in drug discovery at Monsanto/Searle/Pfizer and ICI/Zeneca/AstraZeneca.  She led teams that put Seroquel, a multi-billion dollar antipsychotic, and other molecules into development.  Business development began with in-licensing technology and early drug candidates at AstraZeneca, and continued as head of oncology hematology licensing for Amgen.  She then joined Kosan Biosciences as VP of Business Development, focusing on out-licensing.  Beginning Pullan Consulting in 2006, she and her team serve as BD consultants to a wide array of biotechnology and pharma companies.  She also served as an expert witness, grant reviewer, as CEO and on boards for several small companies and for the AUTM Foundation.  Linda has spoken at many meetings, published papers and chapters, taught many courses in BD. 

The team at Pullan Consulting writes a free monthly newsletter Pullan’s Pieces (sign up on, for thousands of readers. The website also includes links to webinars and whitepapers. 

Agenda Sessions

  • In conversation with Matthias Müllenbeck, Merck KGaA

  • In conversation with Josep-Maria Casanovas, Almirall

  • In conversation with Olaf Koenig, Amgen

  • In conversation with Tomas Landh, Novo Nordisk

  • Innovations in drug delivery


Speakers at this event